Stipple Bio enters multi-target oncology collaboration with Eli Lilly
LLY•Stipple Bio entered a multi-target oncology collaboration with Eli Lilly, under which it will be eligible for up to $5.9 billion in aggregate payments tied to research achievements. Stipple Bio will also receive an upfront payment and an equity investment, while Lilly gets exclusive worldwide rights to develop and commercialize products from the collaboration.
1. Collaboration terms
Stipple Bio entered a multi-target oncology collaboration with Eli Lilly. Stipple Bio will be eligible to receive aggregate payments of up to $5.9 billion upon achievement of research milestones and will receive an upfront payment and an equity investment. Lilly receives exclusive worldwide rights to develop and commercialize products arising from the collaboration.




